Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a ...

Learn how advances in stabilization, automation, and SR-DLS are making PEI-based transient transfection more efficient, ...

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed and reproducibility, today announced the expansion of its ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...

According to Nova One Advisor, the global viral vector & plasmid DNA manufacturing size is calculated at USD 7.54 billion in 2025 and is expected to surpass around USD 27.71 billion by 2034, growing ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

CDMO Andelyn Biosciences says that it has manufactured a viral vector with its AAV Curator ® Platform for the Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program. The Adeno ...

Computational tool improves recombinant virus design efficiency and yield.This innovative in-house development is a key component of Transgene’s ...